Drug Approval | July 24, 2022
Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The product will be launched by NATCO's commercial partner Viatris.
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
Includes thermostabilized Ebola vaccines
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Subscribe To Our Newsletter & Stay Updated
